2025 is a pivotal year for Volition as it focuses on commercializing its Nu.Q® platform in the human diagnostics market, with confidential discussions with more than ten companies, where the combined market value of seven of these companies exceeds $600 billion. The company's business model is based on a dual-path strategy: developing high-impact diagnostic tests for both human and animal health, and monetizing its intellectual property through strategic licensing or collaboration deals with key industry partners.
Cyborg Score Rationale
VolitionRx shows promising commercialization progress with first sales and major partnership discussions, but faces significant financial constraints. The company reported negative net income with losses of $5.38M in the last quarter. Early-stage revenue generation is offset by ongoing cash burn and pre-commercialization status.
Top Insights
First commercial sales of CE-marked Nu.Q® NETs product drive 44% revenue growth.
Sold over 110,000 Nu.Q® Vet Cancer Tests in the first three quarters 2024.
In confidential discussions with more than ten companies, with seven potential partners having combined market value exceeding $600 billion.
Cancer diagnostics and sepsis monitoring represent a $25 billion annual market opportunity.
Named Competitors
Liquid Biopsy Testing — Blood-based cancer detection and monitoring platform
Genomic Cancer Testing — Comprehensive genomic profiling for cancer diagnostics
Veterinary Diagnostics — Animal health diagnostics and imaging solutions
Recent Developments
(December 2025) Business Review of 2025 issued highlighting commercialization progress
(November 2025) First commercial sale of Nu.Q® Cancer assay announced
(May 2025) Q1 2025 financial results showing 44% revenue growth and confidential discussions with major healthcare companies
(June 2025) Peer-reviewed clinical study for H3.1 biomarker published in Critical Care
Open the full interactive VolitionRx Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.